From the BCCA's Breast Cancer Outcomes Unit database in 2009, 16% of all invasive breast cancers with known HER2 status referred to the BCCA were HER2 positive at the time of initial diagnosis, and of those with metastatic disease at the time of referral, 28% were HER2 positive. This evidence concerns the gene ERBB2 and breast cancer.